Alinity m HBV
Abbott Molecular, Inc. · Decision date Sep 24, 2025
What did the FDA approve?
FDA records P200013/S026 as a supplement to PMA P200013, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 24, 2025.
FDA approval order statement
Approval for creating an Alinity m Systems Liner (Liner) as a containment device placed underneath the Alinity m System to catch fluids that may leak from the reagent storage and dispense portions of the instrument.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Microbiology
- Decision date
- Sep 24, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P200013/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- MKT
- Decision code
- APPR
- Decision date
- Sep 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hepatitis Viral B DNA Detection.
- Applicant
- Abbott Molecular, Inc.
- Product code
- MKT
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200013/S026 received
Application receipt date recorded by FDA.
P200013/S026 · FDA decision
Real-Time Process
P200013/S027 · Related supplement
Alinity m HBV
Timeline entries are records held by MedtechLedger for P200013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Alinity m HBVP200013/S027 | Abbott Molecular, Inc. | PMA supplement | Oct 17, 2025 | FDA |
Explore the linked device profile
Other records with product code MKT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HBVP150014/S056 | Roche Molecular Systems, Inc. | PMA supplement | Oct 17, 2025 | FDA |
| Hologic, Inc. | PMA supplement | Oct 7, 2025 | FDA | |
cobas HBVP150014/S058 | Roche Molecular Systems, Inc. | PMA supplement | Sep 19, 2025 | FDA |
cobas HBVP150014/S057 | Roche Molecular Systems, Inc. | PMA supplement | Aug 7, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P200013/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



